Is Zoetis Inc (ZTS) undervalued? · P/E 25, rev $2.47B
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Zoetis Inc (ZTS) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
ZTS currently screens at market cap $64.65B and trailing P/E 24.9. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ZTS 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ZTS to the stock page model before you treat a low multiple as a gift.
Not investment advice.